Waldenstrom's macroglobulinemia in the era of immunotherapy

Iuliana Vaxman, Morie Gertz

Research output: Contribution to journalReview article

Abstract

Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma that presents with symptomatic anemia, thrombocytopenia, constitutional symptoms, extramedullary disease and rarely hyperviscosity syndrome. The presence of both IgM monoclonal protein and ≥10% monoclonal lymphoplasmacytic cells is required for the diagnosis. MyD88 is present in 67-90% of patients but is not pathognomonic for WM. Many patients who fulfill the criteria of WM are asymptomatic and do not require treatment. Recent advances in the understanding of the biology of WM have paved the way for new treatment options. The use of novel agents with or without rituximab enables the use of effective chemotherapy-free regiments upfront and in the relapsed setting. New targeted treatments such as venetoclax and CXCR4 antagonists are being investigated.

Original languageEnglish (US)
Pages (from-to)1292-1304
Number of pages13
JournalLeukemia and Lymphoma
Volume61
Issue number6
DOIs
StatePublished - May 11 2020

Keywords

  • IgM monoclonal gammopathy
  • indolent lymphoma
  • lymphoplasmacytic lymphoma
  • lymphoproliferative disorder
  • macroglobulinemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Waldenstrom's macroglobulinemia in the era of immunotherapy'. Together they form a unique fingerprint.

  • Cite this